Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (41-50 of 269) with videos related to

Pageof 27
Sort By:
Inflammatory Bowel Diseases|February 17, 2024
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not VedolizumabCarlos G Gonzalez, Toer W Stevens, Bram Verstockt, et al.
Diagnostics (Basel, Switzerland)|May 27, 2023
Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care SettingAdriaan Volkers, Mark Löwenberg, Marlou Braad, et al.
Journal of Crohn'S & Colitis|January 9, 2021
A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative ColitisFloris De Voogd, Rune Wilkens, Krisztina Gecse, et al.
Pharmacotherapy|April 5, 2024
Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapyElmar R Alizadeh, Thierry Dervieux, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|February 25, 2016
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM TrialDavid T Rubin, Marc Bradette, Libor Gabalec, et al.
Journal of Crohn'S & Colitis|January 2, 2025
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJoep van Oostrom, Jurij Hanzel, Bram Verstockt, et al.
The American Journal of Gastroenterology|July 2, 2009
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysisLaurent Peyrin-Biroulet, Pierre Deltenre, Sandro Ardizzone, et al.
Inflammatory Bowel Diseases|November 6, 2021
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's DiseaseXavier Roblin, Adrian Serone, Oh Kyu Yoon, et al.
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Scandinavian Journal of Gastroenterology|February 1, 2015
Impact of disease location on fecal calprotectin levels in Crohn's diseaseKrisztina B Gecse, Johannan F Brandse, Sandra van Wilpe, et al.
Pageof 27

Showing results (41-50 of 269) with videos related to

Sort By:
Pageof 27
Inflammatory Bowel Diseases|February 17, 2024
Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not VedolizumabCarlos G Gonzalez, Toer W Stevens, Bram Verstockt, et al.
Diagnostics (Basel, Switzerland)|May 27, 2023
Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care SettingAdriaan Volkers, Mark Löwenberg, Marlou Braad, et al.
Journal of Crohn'S & Colitis|January 9, 2021
A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative ColitisFloris De Voogd, Rune Wilkens, Krisztina Gecse, et al.
Pharmacotherapy|April 5, 2024
Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapyElmar R Alizadeh, Thierry Dervieux, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|February 25, 2016
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM TrialDavid T Rubin, Marc Bradette, Libor Gabalec, et al.
Journal of Crohn'S & Colitis|January 2, 2025
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profilesJoep van Oostrom, Jurij Hanzel, Bram Verstockt, et al.
The American Journal of Gastroenterology|July 2, 2009
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysisLaurent Peyrin-Biroulet, Pierre Deltenre, Sandro Ardizzone, et al.
Inflammatory Bowel Diseases|November 6, 2021
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's DiseaseXavier Roblin, Adrian Serone, Oh Kyu Yoon, et al.
Scandinavian Journal of Gastroenterology|December 30, 2021
Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) studyAdriaan Volkers, Peter Bossuyt, Jitteke de Jong, et al.
Scandinavian Journal of Gastroenterology|February 1, 2015
Impact of disease location on fecal calprotectin levels in Crohn's diseaseKrisztina B Gecse, Johannan F Brandse, Sandra van Wilpe, et al.
Pageof 27